Close Menu

NEW YORK (GenomeWeb) – Cancer diagnostics firm Biodesix has raised $8.6 million in promissory notes, according to a document filed recently with the US Securities and Exchange Commission.

The firm disclosed that it seeks to raise up to $20 million and that it has so far raised $8.6 million in promissory notes convertible into equity securities.

The firm did not disclose what it would use the funds for or the identities of the investors in the financing. It said that 18 investors have participated in the financing. Biodesix did not respond to requests seeking comment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.